Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jnci/djw002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Curr Med Chem
December 2017
Azienda Ospedaliero-Universitaria Careggi, Medical Oncology Unit, Largo Brambilla 3, 50139 Firenze. Italy.
Osteonecrosis of the jaw (ONJ) is a rare treatment related side effect that was firstly described in 2002 through a case report in metastatic bone cancer patient treated with bisphosphonates (BPs) therapy. ONJ is defined as an eight weeks or longer clinical finding of exposed bone in the oral cavity without response to appropriate therapy. The diagnosis is mainly clinical but often requires a radiological confirmation with an orthopantomography.
View Article and Find Full Text PDFRE: Regorafenib Also Can Cause Osteonecrosis of the Jaw.
J Natl Cancer Inst
September 2016
Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy (VF, GN); Department of Surgical, Oncology and Oral Sciences, Sector of Oral Medicine, Palermo University, Palermo, Italy (GC); University of Tennessee Health Science Center, College of Dentistry, Memphis, TN (CM); DH Oncology, Università Campus Bio-Medico, Rome, Italy (DS); Department of Neurosciences (DNS), University of Padua, Padua, Italy (AB).
Regorafenib Also Can Cause Osteonecrosis of the Jaw.
J Natl Cancer Inst
April 2016
S.C Oncologia Medica, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy (LA, AL, EG, MB, FDC).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!